alprazolam has been researched along with Disease Models, Animal in 22 studies
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)
alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Doxapram is an analeptic capable of inducing panic attacks with respiratory symptoms in individuals diagnosed with the disorder; however, its neuroanatomical targets and its effects on experimental animals remain uncharacterized." | 8.02 | Intravenous doxapram administration as a potential model of panic attacks in rats. ( Batista, LA; Brianis, RC; Haibara, AS; Lopes, JB; Moreira, FA, 2021) |
| " Doxapram is an analeptic capable of inducing panic attacks with respiratory symptoms in individuals diagnosed with the disorder; however, its neuroanatomical targets and its effects on experimental animals remain uncharacterized." | 4.02 | Intravenous doxapram administration as a potential model of panic attacks in rats. ( Batista, LA; Brianis, RC; Haibara, AS; Lopes, JB; Moreira, FA, 2021) |
| "Panic disorder is a severe anxiety disorder with recurrent, debilitating panic attacks." | 1.36 | A key role for orexin in panic anxiety. ( Brundin, L; Dietrich, A; Fitz, SD; Goddard, AW; Johnson, PL; Minick, PE; Sanghani, S; Shekhar, A; Träskman-Bendz, L; Truitt, W, 2010) |
| "Alprazolam was associated with a significant attenuation of the HPA-response, suggesting a possible link between initial HPA-axis response disruption and the subsequent unfavorable outcomes." | 1.35 | Alprazolam treatment immediately after stress exposure interferes with the normal HPA-stress response and increases vulnerability to subsequent stress in an animal model of PTSD. ( Cohen, H; Kaplan, Z; Matar, MA; Zohar, J, 2009) |
| "Transgenic R6/2 mice carrying the Huntington's disease (HD) mutation show disrupted circadian rhythms that worsen as the disease progresses." | 1.34 | Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. ( Chesham, JE; Dyball, R; Hastings, MH; Inyushkin, AN; Maywood, ES; Morton, AJ; Pallier, PN; Zheng, Z, 2007) |
| "Treatment with alprazolam significantly reversed these adverse effects of stress, showing that, besides the psychopharmacological properties of this anxiolytic drug against stress, it has consequences for Candida infection." | 1.31 | Effects of psychological stress and alprazolam on development of oral candidiasis in rats. ( Balboa, J; Freire-Garabal, M; García-Vallejo, LA; Liñares, D; Mañá, P; Núñez, MJ; Rey-Méndez, M; Riveiro, P; Rodríguez-Cobos, A; Suárez-Quintanilla, JA, 2002) |
| "Treatment with alprazolam (1 mg/Kg) partially reversed this adverse effect of stress." | 1.30 | Effects of alprazolam on the free-choice ethanol consumption induced by isolation stress in aged rats. ( Becerra, MA; De Miguel, S; Freire-Garabal, M; Legazpi, MP; Mayán, JM; Núñez, LA; Núñez, MJ; Quintans, MR; Rey-Méndez, M; Riveiro, P; Varela, M, 1999) |
| "Treatment with carbamazepine attenuated (P less than 0." | 1.28 | Chronic benzodiazepine administration. IX. Attenuation of alprazolam discontinuation effects by carbamazepine. ( Browne, TR; Galpern, WR; Greenblatt, DJ; Miller, LG; Shader, RI; Szabo, GK, 1991) |
| "6." | 1.28 | Platelet-activating factor mediates glycerol-induced acute renal failure in rats. ( Bernabeu, F; Braquet, P; Gómez-Garre, D; López-Farré, A; López-Novoa, JM; Perez-Rodrigo, P; Ramón y Cajal, S, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 5 (22.73) | 18.2507 |
| 2000's | 8 (36.36) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Batista, LA | 2 |
| Lopes, JB | 1 |
| Brianis, RC | 1 |
| Haibara, AS | 2 |
| Moreira, FA | 2 |
| Navarrete, F | 1 |
| García-Gutiérrez, MS | 1 |
| Laborda, J | 1 |
| Manzanares, J | 1 |
| Bregin, A | 1 |
| Mazitov, T | 1 |
| Aug, I | 1 |
| Philips, MA | 1 |
| Innos, J | 1 |
| Vasar, E | 1 |
| El Zahaf, NA | 1 |
| Salem Elhwuegi, A | 1 |
| Sant'Ana, AB | 1 |
| Weffort, LF | 1 |
| de Oliveira Sergio, T | 1 |
| Gomes, RC | 1 |
| Frias, AT | 1 |
| Matthiesen, M | 1 |
| Vilela-Costa, HH | 1 |
| Yamashita, PS | 1 |
| Vasconcelos, AT | 1 |
| de Bortoli, V | 1 |
| Del-Ben, CM | 1 |
| Zangrossi, H | 1 |
| Schenberg, LC | 1 |
| Matar, MA | 1 |
| Zohar, J | 1 |
| Kaplan, Z | 1 |
| Cohen, H | 1 |
| Pallier, PN | 2 |
| Morton, AJ | 2 |
| Porecha, S | 1 |
| shah, T | 1 |
| Jogani, V | 1 |
| Naik, S | 1 |
| Misra, A | 1 |
| Johnson, PL | 1 |
| Truitt, W | 1 |
| Fitz, SD | 1 |
| Minick, PE | 1 |
| Dietrich, A | 1 |
| Sanghani, S | 1 |
| Träskman-Bendz, L | 1 |
| Goddard, AW | 1 |
| Brundin, L | 1 |
| Shekhar, A | 1 |
| Steiner, MA | 1 |
| Lecourt, H | 1 |
| Rakotoariniaina, A | 1 |
| Jenck, F | 1 |
| Dolezal, T | 1 |
| Krsiak, M | 1 |
| Maywood, ES | 1 |
| Zheng, Z | 1 |
| Chesham, JE | 1 |
| Inyushkin, AN | 1 |
| Dyball, R | 1 |
| Hastings, MH | 1 |
| Leonard, SK | 1 |
| Dwyer, JM | 1 |
| Sukoff Rizzo, SJ | 1 |
| Platt, B | 1 |
| Logue, SF | 1 |
| Neal, SJ | 1 |
| Malberg, JE | 1 |
| Beyer, CE | 1 |
| Schechter, LE | 1 |
| Rosenzweig-Lipson, S | 1 |
| Ring, RH | 1 |
| Sethy, VH | 1 |
| Hodges, DH | 1 |
| Sabatino, M | 1 |
| Cannizzaro, C | 1 |
| Flugy, A | 1 |
| Gagliand, M | 1 |
| Mineo, A | 1 |
| Cannizzaro, G | 1 |
| Watson, GS | 1 |
| Roach, JT | 1 |
| Sufka, KJ | 1 |
| Núñez, MJ | 2 |
| Riveiro, P | 2 |
| Becerra, MA | 1 |
| De Miguel, S | 1 |
| Quintans, MR | 1 |
| Núñez, LA | 1 |
| Legazpi, MP | 1 |
| Mayán, JM | 1 |
| Rey-Méndez, M | 2 |
| Varela, M | 1 |
| Freire-Garabal, M | 2 |
| Raghavendra, V | 1 |
| Kaur, G | 1 |
| Kulkarni, SK | 1 |
| Balboa, J | 1 |
| Liñares, D | 1 |
| Mañá, P | 1 |
| Rodríguez-Cobos, A | 1 |
| Suárez-Quintanilla, JA | 1 |
| García-Vallejo, LA | 1 |
| Galpern, WR | 1 |
| Miller, LG | 1 |
| Greenblatt, DJ | 1 |
| Szabo, GK | 1 |
| Browne, TR | 1 |
| Shader, RI | 1 |
| López-Farré, A | 1 |
| Gómez-Garre, D | 1 |
| Bernabeu, F | 1 |
| Ramón y Cajal, S | 1 |
| Perez-Rodrigo, P | 1 |
| Braquet, P | 1 |
| López-Novoa, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Orexin in Human Panic Disorder[NCT02593682] | Phase 4 | 3 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 other studies available for alprazolam and Disease Models, Animal
| Article | Year |
|---|---|
Intravenous doxapram administration as a potential model of panic attacks in rats.
Topics: Administration, Intravenous; Alprazolam; Animals; Benzamides; Carbamates; Central Nervous System Sti | 2021 |
Deletion of Dlk2 increases the vulnerability to anxiety-like behaviors and impairs the anxiolytic action of alprazolam.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Depression; Disease Models, Ani | 2017 |
Increased sensitivity to psychostimulants and GABAergic drugs in Lsamp-deficient mice.
Topics: Alprazolam; Animals; Behavior, Animal; Cell Adhesion Molecules, Neuronal; Central Nervous System Dep | 2019 |
The effect of GABAmimetics on the duration of immobility in the forced swim test in albino mice.
Topics: Alprazolam; Animals; Depression; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; | 2014 |
Panic-modulating effects of alprazolam, moclobemide and sumatriptan in the rat elevated T-maze.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Brain; Disease Models, Animal; Escape Reaction; Explorator | 2016 |
Effects of alprazolam and cannabinoid-related compounds in an animal model of panic attack.
Topics: Alprazolam; Analgesics; Animals; Arachidonic Acids; Benzamides; Benzoxazines; Blood Pressure; Cannab | 2017 |
Alprazolam treatment immediately after stress exposure interferes with the normal HPA-stress response and increases vulnerability to subsequent stress in an animal model of PTSD.
Topics: Acoustic Stimulation; Alprazolam; Analysis of Variance; Animals; Anti-Anxiety Agents; Behavior, Anim | 2009 |
Management of sleep/wake cycles improves cognitive function in a transgenic mouse model of Huntington's disease.
Topics: Affect; Alprazolam; Animals; Benzhydryl Compounds; Body Weight; Central Nervous System Stimulants; C | 2009 |
Microemulsion based intranasal delivery system for treatment of insomnia.
Topics: Administration, Intranasal; Alprazolam; Animals; Diazepam; Disease Models, Animal; Drug Compounding; | 2009 |
A key role for orexin in panic anxiety.
Topics: Adult; Alprazolam; Animals; Anxiety; Disease Models, Animal; Female; Humans; Hypothalamus; Intracell | 2010 |
Favoured genetic background for testing anxiolytics in the fear-potentiated and light-enhanced startle paradigms in the rat.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Conditioning, Classical; Disease Models, Animal; Dose-Resp | 2011 |
Augmentation of analgesic effect of ibuprofen by alprazolam in experimental model of pain.
Topics: Acetic Acid; Acute Disease; Administration, Oral; Alprazolam; Analgesics, Non-Narcotic; Animals; Dis | 2002 |
Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease.
Topics: Age Factors; Alprazolam; Animals; Cell Cycle Proteins; Chloral Hydrate; Choice Behavior; Circadian R | 2007 |
Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Arousal | 2008 |
Alprazolam in a biochemical model of depression.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Benzodiazepines; Depression; Diazepam; Disease Models, Ani | 1982 |
NMDA-GABA interactions in an animal model of behaviour: a gating mechanism from motivation toward psychotic-like symptoms.
Topics: Alprazolam; Animals; Behavior, Animal; Desipramine; Disease Models, Animal; Dizocilpine Maleate; gam | 1994 |
Benzodiazepine receptor function in the chick social separation-stress procedure.
Topics: Alprazolam; Analgesia; Animals; Anti-Anxiety Agents; Chickens; Chlordiazepoxide; Disease Models, Ani | 1999 |
Effects of alprazolam on the free-choice ethanol consumption induced by isolation stress in aged rats.
Topics: Aging; Alcohol Drinking; Alcoholism; Alprazolam; Animals; Anti-Anxiety Agents; Disease Models, Anima | 1999 |
Anti-depressant action of melatonin in chronic forced swimming-induced behavioral despair in mice, role of peripheral benzodiazepine receptor modulation.
Topics: Alprazolam; Analysis of Variance; Animals; Anti-Anxiety Agents; Antioxidants; Benzodiazepinones; Bic | 2000 |
Effects of psychological stress and alprazolam on development of oral candidiasis in rats.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Candida albicans; Candidiasis, Oral; Disease Models, Anima | 2002 |
Chronic benzodiazepine administration. IX. Attenuation of alprazolam discontinuation effects by carbamazepine.
Topics: Alprazolam; Animals; Anxiety; Carbamazepine; Cerebral Cortex; Disease Models, Animal; Drug Administr | 1991 |
Platelet-activating factor mediates glycerol-induced acute renal failure in rats.
Topics: Acute Kidney Injury; Alprazolam; Animals; Disease Models, Animal; Diterpenes; Ginkgolides; Glomerula | 1990 |